O'Flaherty J T, Jacobson D P, Redman J F
Bowman Gray School of Medicine, Wake Forest University, Winston-Salem, North Carolina 27103.
J Biol Chem. 1989 Apr 25;264(12):6836-43.
Protein kinase C (PKC) (Ca2+/phospholipid-dependent enzyme) activators stimulated human neutrophils to reduce the availability of high affinity receptors for platelet-activating factor. These effects were concentration dependent, irreversible, temperature sensitive, and antagonized by a PKC blocker. The activators also inhibited 1-O-alkyl-65% hexadecyl, 25% octadecyl-2-acetyl-sn-glycero-3-phosphocholine (PAF)-induced Ca2+ transients; this inhibition correlated precisely with receptor depletion. Contrastingly, PKC activators could enhance as well as inhibit PAF-induced degranulation. Inhibition of degranulation occurred only at concentrations of the activators which depressed high affinity PAF binding by greater than 75%. Cells treated with lesser activator concentrations responded to PAF with reduced but still substantial rises in cytosolic Ca2+, markedly increased degranulation, and markedly increased PKC mobilization. The last two responses, however, failed to occur in cells that were (a) calcium depleted, (b) treated with high activator concentrations (which inhibited virtually all PAF binding and PAF-induced Ca2+ transients), or (c) treated with PAF 5 min before a PKC activator (PAF-induced rises in cytosolic Ca2+ reversed in less than 5 min). Thus, activated PKC down-regulates high affinity PAF receptors. This tends to reduce neutrophil responses to PAF. On the other hand, PAF, perhaps by raising cytosolic Ca2+, acts synergistically with PKC activators in mobilizing PKC. This may tend to enhance function but seems capable of influencing only those responses that are elicited by PKC activators (e.g. degranulation but not Ca2+ transients). The complex and bidirectional effects of PKC activators on other receptor-mediated, calcium mobilizing agonists in various cell types may reflect these opposing mechanisms.
蛋白激酶C(PKC)(一种钙/磷脂依赖性酶)激活剂可刺激人中性粒细胞,降低血小板激活因子高亲和力受体的可用性。这些效应呈浓度依赖性、不可逆、对温度敏感,并被PKC阻滞剂拮抗。激活剂还抑制1 - O - 烷基 - 65%十六烷基、25%十八烷基 - 2 - 乙酰 - sn - 甘油 - 3 - 磷酸胆碱(PAF)诱导的钙离子瞬变;这种抑制与受体耗竭精确相关。相反,PKC激活剂既能增强也能抑制PAF诱导的脱颗粒作用。脱颗粒作用的抑制仅发生在激活剂浓度能使高亲和力PAF结合降低超过75%的情况下。用较低浓度激活剂处理的细胞对PAF的反应是胞质钙离子浓度虽有降低但仍有显著升高、脱颗粒明显增加以及PKC动员显著增加。然而,在以下细胞中不会出现后两种反应:(a)钙耗竭的细胞;(b)用高浓度激活剂处理的细胞(几乎抑制了所有PAF结合和PAF诱导的钙离子瞬变);或(c)在PKC激活剂处理前5分钟先用PAF处理的细胞(PAF诱导的胞质钙离子升高在不到5分钟内逆转)。因此,活化的PKC下调高亲和力PAF受体。这往往会降低中性粒细胞对PAF的反应。另一方面,PAF可能通过升高胞质钙离子浓度,在动员PKC方面与PKC激活剂协同作用。这可能倾向于增强功能,但似乎仅能影响由PKC激活剂引发的那些反应(如脱颗粒而非钙离子瞬变)。PKC激活剂对各种细胞类型中其他受体介导的、钙离子动员激动剂的复杂双向作用可能反映了这些相反的机制。